Company applying the emerging field of artificial intelligence with extreme miniaturization of ultrasound to solve common every day problems in healthcare
Signostics, a subsidiary of EchoNous and a KKR portfolio company, has seen the rapid conversion of nearly 20% of U.S. healthcare systems to its Uscan intelligent ultrasound tool since the product’s launch just last year. Utilizing a fusion of artificial intelligence and the extreme miniaturization of ultrasound, the new Uscan more precisely measures bladder volume and bladder wall thickness, resulting in significantly higher first-time measurement accuracy for nurses using the device. The growing market preference for Uscan is highlighted by a three-year agreement with Ohio-based Excelerate Strategic Health Sourcing enabling this top tier GPO to deploy the device for improved and more accurate bladder imaging.
“Unlike conventional bladder scanners, we are applying the emerging fields of artificial intelligence, including deep and machine learning, alongside extreme miniaturization of ultrasound to solve common every day problems in healthcare,” said Signostics CEO Kevin Goodwin. “The UScan is a simple-to-use, cost and time-efficient device that, beginning with bladder and kidney care, is dramatically increasing first-time accuracy, saving nurses time and improving catheter decisions by using ultrasound in patient care.”
Uscan requires only a simple fanning motion over the bladder to derive a highly accurate first-time measurement. The device captures 32 times more imaging data than conventional bladders scanners, recording 256 bladder data slices in each fan, then running this rich data set through a computer vision-based algorithm to produce a high-resolution 3D model of the bladder. Offering clinicians industry-leading accuracy, healthcare providers can then make fast and accurate decisions to potentially reduce unnecessary catheterizations and associated urinary tract infections, which cost hospitals millions of dollars each year.
“Beyond bladder and kidney care, we intend to apply our miniaturized, AI-driven, intelligent ultrasound tool to the challenges of peripheral IV access in early 2018,” continued Goodwin.
“Based on our use of machine learning we are driving point and shoot simplicity, for a ‘see one – do one – teach one’ experience, which will lower the training burden for all types of users. We foresee the application of AI enabling a big step forward in training and usability of our devices.”
About EchoNous & Signostics
EchoNous is applying the emerging field of artificial intelligence (AI) with the extreme miniaturization of ultrasound to solve common every day problems in healthcare. CEO and industry innovator Kevin Goodwin leads the company based on more than 30 years of novel disruptive category creating innovation in the ultrasound industry. Headquartered in Seattle, Washington, EchoNous is backed by an initial $35M round from the global investment firm KKR. For more information, visit www.echonous.com.
Signostics Inc. is a wholly owned subsidiary of EchoNous, a Delaware-based corporation and KKR portfolio company. The company’s Uscan device simply and precisely measures bladder volume and bladder wall thickness, saving time and money and leading to improved patient satisfaction. Signostics has regulatory approvals in the U.S., Australia, Canada, Europe, Singapore and Japan, and exports to countries around the world. For more information, visit www.signosticsmedical.com.
Signostics and Uscan are Trademarks of Signostics Limited.
Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.